Felodipine

Identification

Name

Felodipine

Accession Number

DB01023  (APRD00374)

Type

Small Molecule

Groups

Approved, Investigational

Description

Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction. Felodipine is the most potent CCB in use and is unique in that it exhibits fluorescent activity. In addition to binding to L-type calcium channels, felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase, and blocks calcium influx through voltage-gated T-type calcium channels. Felodipine is used to treat mild to moderate essential hypertension.

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for DB01023 (Felodipine)

×

Close

Synonyms

• (+-)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
• 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate
• 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester
• Felodipina
• Felodipine
• Felodipinum

Product Images

PreviousNext

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Felodipineextended-release Tablets	Tablet, extended release	10 mg/1	Oral	Ranbaxy Inc.	2008-09-10	Not applicable
Felodipineextended-release Tablets	Tablet, extended release	5 mg/1	Oral	Ranbaxy Inc.	2008-09-10	Not applicable
Felodipineextended-release Tablets	Tablet, extended release	2.5 mg/1	Oral	Ranbaxy Inc.	2008-09-10	Not applicable
Plendil	Tablet, extended release	2.5 mg/1	Oral	Astra Zeneca Lp	1994-10-04	2016-11-04
Plendil	Tablet, extended release	10 mg/1	Oral	Astra Zeneca Lp	1991-09-16	2016-11-04
Plendil	Tablet, extended release	5 mg/1	Oral	Astra Zeneca Lp	1991-09-16	2016-11-04
Plendil	Tablet, extended release	10 mg/1	Oral	bryant ranch prepack	1991-09-16	Not applicable
Plendil 10 mg	Tablet, extended release	10 mg	Oral	Astra Zeneca	1992-12-31	Not applicable
Plendil 2.5 mg	Tablet, extended release	2.5 mg	Oral	Astra Zeneca	1994-12-31	Not applicable
Plendil 5 mg	Tablet, extended release	5 mg	Oral	Astra Zeneca	1992-12-31	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-felodipine	Tablet, extended release	5 mg	Oral	Apotex Corporation	2016-04-22	Not applicable
Apo-felodipine	Tablet, extended release	2.5 mg	Oral	Apotex Corporation	2016-04-22	Not applicable
Apo-felodipine	Tablet, extended release	10 mg	Oral	Apotex Corporation	2016-04-22	Not applicable
Felodipine	Tablet, film coated, extended release	2.5 mg/1	Oral	Av Kare, Inc.	2014-03-31	2016-01-15
Felodipine	Tablet, film coated, extended release	2.5 mg/1	Oral	Glenmark Pharmaceuticals Inc.,Usa	2010-12-20	Not applicable
Felodipine	Tablet, film coated, extended release	5 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2009-11-16	Not applicable
Felodipine	Tablet, film coated, extended release	2.5 mg/1	Oral	Richmond Pharmaceuticals	2004-11-02	Not applicable
Felodipine	Tablet, extended release	10 mg/1	Oral	A S Medication Solutions	2011-11-28	2017-06-20
Felodipine	Tablet, extended release	5 mg/1	Oral	Par Pharmaceutical	2011-12-15	Not applicable
Felodipine	Tablet, film coated, extended release	10 mg/1	Oral	Jubilant Cadista Pharmaceuticals Inc.	2016-08-19	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Altace Plus Felodipine 2.5mg + 2.5mg	Felodipine (2.5 mg) + Ramipril (2.5 mg)	Tablet	Oral	Sanofi Aventis	2006-06-27	2012-10-10
Altace Plus Felodipine 5mg + 5mg	Felodipine (5 mg) + Ramipril (5 mg)	Tablet	Oral	Sanofi Aventis	2006-06-27	2012-10-15

International/Other Brands

Felodur ER / Felogard / Penedil / Plendil Depottab (AstraZeneca) / Plendil ER (AstraZeneca) / Plendil Retard (AstraZeneca) / Splendil

Categories

• ACE Inhibitors and Calcium Channel Blockers
• Antiarrhythmic agents
• Antihypertensive Agents
• BSEP/ABCB11 Substrates
• Calcium Channel Blockers
• Calcium Channel Blockers (Dihydropyridine)
• Calcium Channel Blockers, Dihydropyridine and Nondihydropyridine
• Cardiovascular Agents
• Cardiovascular System
• CYP3A Substrates (Sensitive)
• Cytochrome P-450 CYP2C8 Inhibitors
• Cytochrome P-450 CYP2C8 Inhibitors (strong)
• Cytochrome P-450 CYP2D6 Inhibitors
• Cytochrome P-450 CYP2D6 Inhibitors (weak)
• Cytochrome P-450 CYP3A Substrates
• Cytochrome P-450 CYP3A4 Substrates
• Cytochrome P-450 CYP3A4 Substrates (strength unknown)
• Cytochrome P-450 CYP3A5 Substrates
• Cytochrome P-450 CYP3A7 Substrates
• Cytochrome P-450 Enzyme Inhibitors
• Dihydropyridine Derivatives
• Dihydropyridines
• Hypotensive Agents
• Membrane Transport Modulators
• P-glycoprotein/ABCB1 Inhibitors
• Pyridines
• Selective Calcium Channel Blockers With Mainly Vascular Effects
• Vasodilating Agents

UNII

OL961R6O2C

CAS number

72509-76-3

Weight

Average: 384.254
Monoisotopic: 383.069113515

Chemical Formula

C₁₈H₁₉Cl₂NO₄

InChI Key

RZTAMFZIAATZDJ-UHFFFAOYSA-N

InChI

InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3

IUPAC Name

3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate

SMILES

CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC

Pharmacology

Indication

For the treatment of mild to moderate essential hypertension.

Associated Conditions

• High Blood Pressure (Hypertension)

Pharmacodynamics

Felodipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. It was widely accepted that CCBs target L-type calcium channels, the major channel in muscle cells that mediates contraction; however, some studies have shown that felodipine also binds to and inhibits T-type calcium channels. T-type calcium channels are most commonly found on neurons, cells with pacemaker activity and on osteocytes. The pharmacologic significance of T-type calcium channel blockade is unknown. Felodipine also binds to calmodulin and inhibits calmodulin-dependent calcium release from the sarcoplasmic reticulum. The effect of this interaction appears to be minor. Another study demonstrated that felodipine attenuates the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase (CaMPDE) by binding to the PDE-1B1 and PDE-1A2 enzyme subunits. CaMPDE is one of the key enzymes involved in cyclic nucleotides and calcium second messenger systems. Felodipine also acts as an antagonist to the mineralcorticoid receptor by competing with aldosterone for binding and blocking aldosterone-induced coactivator recruitment of the mineralcorticoid receptor. Felodipine is able to bind to skeletal and cardiac muscle isoforms of troponin C, one of the key regulatory proteins in muscle contraction. Though felodipine exhibits binding to many endogenous molecules, its vasodilatory effects are still thought to be brought about primarily through inhibition of voltage-gated L-type calcium channels. Similar to other DHP CCBs, felodipine binds directly to inactive calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives felodipine additional arterial selectivity. At therapeutic sub-toxic concentrations, felodipine has little effect on cardiac myocytes and conduction cells.

Mechanism of action

Felodipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through voltage-gated L-type calcium channels. It reversibly competes against nitrendipine and other DHP CCBs for DHP binding sites in vascular smooth muscle and cultured rabbit atrial cells. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of felodipine result in an overall decrease in blood pressure. Felodipine may be used to treat mild to moderate essential hypertension.

Target	Actions	Organism
AVoltage-dependent L-type calcium channel subunit alpha-1C	inhibitor	Human
AVoltage-dependent calcium channel subunit alpha-2/delta-1	inhibitor	Human
AVoltage-dependent L-type calcium channel subunit beta-2	inhibitor	Human
AVoltage-dependent L-type calcium channel subunit alpha-1D	inhibitor	Human
AVoltage-dependent L-type calcium channel subunit alpha-1S	inhibitor	Human
UVoltage-dependent T-type calcium channel subunit alpha-1H	inhibitor	Human
UVoltage-dependent calcium channel subunit alpha-2/delta-2	inhibitor	Human
UCalmodulin	other	Human
UCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	inhibitor	Human
UCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	inhibitor	Human
UMineralocorticoid receptor	antagonist	Human
UTroponin C, skeletal muscle	other	Human
UTroponin C, slow skeletal and cardiac muscles	other	Human

Absorption

Is completely absorbed from the gastrointestinal tract; however, extensive first-pass metabolism through the portal circulation results in a low systemic availability of 15%. Bioavailability is unaffected by food.

Volume of distribution

• 10 L/kg

Protein binding

99%, primarily to the albumin fraction.

Metabolism

Hepatic metabolism primarily via cytochrome P450 3A4. Six metabolites with no appreciable vasodilatory effects have been identified.

• Felodipine
  dehydrofelodipine

Route of elimination

Although higher concentrations of the metabolites are present in the plasma due to decreased urinary excretion, these are inactive. Animal studies have demonstrated that felodipine crosses the blood-brain barrier and the placenta.

Half life

17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.

Clearance

• 0.8 L/min [Young healthy subjects]

Toxicity

Symptoms of overdose include excessive peripheral vasodilation with marked hypotension and possibly bradycardia. Oral rat LD₅₀ is 1050 mg/kg.

Affected organisms

• Humans and other mammals

Pathways

Pathway	Category
Felodipine Metabolism Pathway	Drug metabolism
Felodipine Action Pathway	Drug action

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
(R)-warfarin	The metabolism of (R)-warfarin can be decreased when combined with Felodipine.	Experimental
(S)-Warfarin	The metabolism of (S)-Warfarin can be decreased when combined with Felodipine.	Experimental, Investigational
Abafungin	The therapeutic efficacy of Abafungin can be increased when used in combination with Felodipine.	Investigational
Abemaciclib	The serum concentration of Abemaciclib can be increased when it is combined with Felodipine.	Approved, Investigational
Acebutolol	The serum concentration of Acebutolol can be increased when it is combined with Felodipine.	Approved, Investigational
Aceclofenac	The therapeutic efficacy of Felodipine can be decreased when used in combination with Aceclofenac.	Approved, Investigational
Acemetacin	The therapeutic efficacy of Felodipine can be decreased when used in combination with Acemetacin.	Approved, Experimental, Investigational
Acepromazine	The risk or severity of hypotension can be increased when Acepromazine is combined with Felodipine.	Approved, Vet Approved
Acetylsalicylic acid	The therapeutic efficacy of Felodipine can be decreased when used in combination with Acetylsalicylic acid.	Approved, Vet Approved
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Felodipine.	Approved
Albaconazole	The therapeutic efficacy of Albaconazole can be increased when used in combination with Felodipine.	Investigational
Alclofenac	The therapeutic efficacy of Felodipine can be decreased when used in combination with Alclofenac.	Approved, Withdrawn
Alcuronium	Felodipine may increase the neuromuscular blocking activities of Alcuronium.	Experimental
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Felodipine.	Approved
Aldosterone	The serum concentration of Aldosterone can be increased when it is combined with Felodipine.	Experimental, Investigational
Alfuzosin	Alfuzosin may increase the hypotensive activities of Felodipine.	Approved, Investigational
Aliskiren	Felodipine may increase the hypotensive activities of Aliskiren.	Approved, Investigational
Alitretinoin	The serum concentration of Alitretinoin can be increased when it is combined with Felodipine.	Approved, Investigational
Alminoprofen	The therapeutic efficacy of Felodipine can be decreased when used in combination with Alminoprofen.	Experimental
Alprenolol	Felodipine may increase the hypotensive activities of Alprenolol.	Approved, Withdrawn
Ambrisentan	The serum concentration of Ambrisentan can be increased when it is combined with Felodipine.	Approved, Investigational
Amifostine	Felodipine may increase the hypotensive activities of Amifostine.	Approved, Investigational
Amiloride	The risk or severity of adverse effects can be increased when Amiloride is combined with Felodipine.	Approved
Aminophenazone	The therapeutic efficacy of Felodipine can be decreased when used in combination with Aminophenazone.	Approved, Withdrawn
Amiodarone	The risk or severity of adverse effects can be increased when Amiodarone is combined with Felodipine.	Approved, Investigational
Amitriptyline	The risk or severity of hypotension can be increased when Amitriptyline is combined with Felodipine.	Approved
Amlodipine	Amlodipine may increase the hypotensive activities of Felodipine.	Approved
Amobarbital	Amobarbital may increase the hypotensive activities of Felodipine.	Approved, Illicit
Amodiaquine	The serum concentration of Amodiaquine can be increased when it is combined with Felodipine.	Approved, Investigational
Amoxapine	The risk or severity of hypotension can be increased when Amoxapine is combined with Felodipine.	Approved
Amphotericin B	Felodipine may decrease the nephrotoxic activities of Amphotericin B.	Approved, Investigational
Amprenavir	The serum concentration of Amprenavir can be increased when it is combined with Felodipine.	Approved, Investigational
Amyl Nitrite	The risk or severity of adverse effects can be increased when Felodipine is combined with Amyl Nitrite.	Approved
Antipyrine	The therapeutic efficacy of Felodipine can be decreased when used in combination with Antipyrine.	Approved, Investigational
Antrafenine	The therapeutic efficacy of Felodipine can be decreased when used in combination with Antrafenine.	Approved
Apalutamide	The serum concentration of Apalutamide can be increased when it is combined with Felodipine.	Approved, Investigational
Apixaban	The metabolism of Apixaban can be decreased when combined with Felodipine.	Approved
Apomorphine	The risk or severity of adverse effects can be increased when Apomorphine is combined with Felodipine.	Approved, Investigational
Apraclonidine	The risk or severity of adverse effects can be increased when Apraclonidine is combined with Felodipine.	Approved
Aprepitant	The serum concentration of Felodipine can be increased when it is combined with Aprepitant.	Approved, Investigational
Aripiprazole	Aripiprazole may increase the hypotensive activities of Felodipine.	Approved, Investigational
Aripiprazole lauroxil	The risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Felodipine.	Approved, Investigational
Arotinolol	The risk or severity of hypotension can be increased when Arotinolol is combined with Felodipine.	Investigational
Arsenic trioxide	The serum concentration of Arsenic trioxide can be increased when it is combined with Felodipine.	Approved, Investigational
Ascorbic acid	The serum concentration of Ascorbic acid can be increased when it is combined with Felodipine.	Approved, Nutraceutical
Asenapine	The risk or severity of hypotension can be increased when Asenapine is combined with Felodipine.	Approved
Asunaprevir	The serum concentration of Asunaprevir can be increased when it is combined with Felodipine.	Approved, Investigational, Withdrawn
Atazanavir	The metabolism of Felodipine can be decreased when combined with Atazanavir.	Approved, Investigational
Atenolol	Atenolol may increase the hypotensive activities of Felodipine.	Approved
Atorvastatin	The serum concentration of Atorvastatin can be increased when it is combined with Felodipine.	Approved
Atracurium	Felodipine may increase the neuromuscular blocking activities of Atracurium.	Approved, Experimental, Investigational
Atracurium besylate	Felodipine may increase the neuromuscular blocking activities of Atracurium besylate.	Approved
Avanafil	Avanafil may increase the antihypertensive activities of Felodipine.	Approved
Avatrombopag	The serum concentration of Avatrombopag can be increased when it is combined with Felodipine.	Approved, Investigational
Axitinib	The serum concentration of Axitinib can be increased when it is combined with Felodipine.	Approved, Investigational
Azapropazone	The therapeutic efficacy of Felodipine can be decreased when used in combination with Azapropazone.	Withdrawn
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Felodipine is combined with Azilsartan medoxomil.	Approved, Investigational
Balaglitazone	The metabolism of Balaglitazone can be decreased when combined with Felodipine.	Investigational
Balsalazide	The therapeutic efficacy of Felodipine can be decreased when used in combination with Balsalazide.	Approved, Investigational
Barbexaclone	Barbexaclone may increase the hypotensive activities of Felodipine.	Experimental
Barbital	Barbital may increase the hypotensive activities of Felodipine.	Illicit
Baricitinib	The serum concentration of Baricitinib can be increased when it is combined with Felodipine.	Approved, Investigational
Barnidipine	Felodipine may increase the antihypertensive activities of Barnidipine.	Approved
Belinostat	The serum concentration of Belinostat can be increased when it is combined with Felodipine.	Approved, Investigational
Benazepril	Benazepril may increase the hypotensive activities of Felodipine.	Approved, Investigational
Benazeprilat	Felodipine may increase the hypotensive activities of Benazeprilat.	Experimental
Bendazac	The therapeutic efficacy of Felodipine can be decreased when used in combination with Bendazac.	Experimental
Bendroflumethiazide	Bendroflumethiazide may increase the hypotensive activities of Felodipine.	Approved
Benmoxin	Benmoxin may increase the hypotensive activities of Felodipine.	Withdrawn
Benorilate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Benorilate.	Experimental
Benoxaprofen	The therapeutic efficacy of Felodipine can be decreased when used in combination with Benoxaprofen.	Withdrawn
Benzydamine	The therapeutic efficacy of Felodipine can be decreased when used in combination with Benzydamine.	Approved
Bepridil	Felodipine may increase the hypotensive activities of Bepridil.	Approved, Withdrawn
Betamethasone	The serum concentration of Betamethasone can be increased when it is combined with Felodipine.	Approved, Vet Approved
Betaxolol	Betaxolol may increase the hypotensive activities of Felodipine.	Approved, Investigational
Bethanidine	Bethanidine may increase the hypotensive activities of Felodipine.	Approved
Bevantolol	The risk or severity of hypotension can be increased when Bevantolol is combined with Felodipine.	Approved
Bietaserpine	Bietaserpine may increase the hypotensive activities of Felodipine.	Experimental
Bifonazole	The therapeutic efficacy of Bifonazole can be increased when used in combination with Felodipine.	Approved, Investigational
Bimatoprost	Bimatoprost may increase the hypotensive activities of Felodipine.	Approved, Investigational
Bisacodyl	The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Felodipine.	Approved
Bisoprolol	Bisoprolol may increase the hypotensive activities of Felodipine.	Approved
Bisoxatin	The therapeutic efficacy of Bisoxatin can be decreased when used in combination with Felodipine.	Approved
Boceprevir	The metabolism of Felodipine can be decreased when combined with Boceprevir.	Approved, Withdrawn
Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Felodipine.	Approved, Investigational
Bosentan	The serum concentration of Felodipine can be decreased when it is combined with Bosentan.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Felodipine.	Approved
BQ-123	Felodipine may increase the hypotensive activities of BQ-123.	Investigational
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Felodipine.	Approved, Investigational
Bretylium	Felodipine may increase the hypotensive activities of Bretylium.	Approved
Brexpiprazole	The risk or severity of hypotension can be increased when Brexpiprazole is combined with Felodipine.	Approved, Investigational
Brigatinib	The serum concentration of Felodipine can be decreased when it is combined with Brigatinib.	Approved, Investigational
Bromfenac	The therapeutic efficacy of Felodipine can be decreased when used in combination with Bromfenac.	Approved
Bromocriptine	The risk or severity of hypotension can be increased when Bromocriptine is combined with Felodipine.	Approved, Investigational
Bromperidol	The serum concentration of Bromperidol can be increased when it is combined with Felodipine.	Approved, Investigational
Bucindolol	The risk or severity of hypotension can be increased when Bucindolol is combined with Felodipine.	Investigational
Bufexamac	The therapeutic efficacy of Felodipine can be decreased when used in combination with Bufexamac.	Approved, Experimental
Bumadizone	The therapeutic efficacy of Felodipine can be decreased when used in combination with Bumadizone.	Experimental
Bumetanide	The risk or severity of adverse effects can be increased when Bumetanide is combined with Felodipine.	Approved
Bunazosin	The risk or severity of hypotension can be increased when Bunazosin is combined with Felodipine.	Investigational
Bupivacaine	The risk or severity of adverse effects can be increased when Bupivacaine is combined with Felodipine.	Approved, Investigational
Bupranolol	Felodipine may increase the hypotensive activities of Bupranolol.	Approved
Butoconazole	The therapeutic efficacy of Butoconazole can be increased when used in combination with Felodipine.	Approved
Cabazitaxel	The serum concentration of Cabazitaxel can be increased when it is combined with Felodipine.	Approved
Cadralazine	Cadralazine may increase the hypotensive activities of Felodipine.	Experimental
Calcium Acetate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Acetate.	Approved, Investigational
Calcium Carbonate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Carbonate.	Approved, Investigational
Calcium Chloride	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Chloride.	Approved
Calcium Citrate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Citrate.	Approved
Calcium glubionate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium glubionate.	Approved
Calcium Gluceptate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Gluceptate.	Approved
Calcium gluconate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium gluconate.	Approved, Vet Approved
Calcium lactate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium lactate.	Approved, Investigational, Vet Approved
Calcium lactate gluconate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium lactate gluconate.	Experimental
Calcium levulinate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium levulinate.	Approved, Experimental
Calcium pangamate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium pangamate.	Experimental
Calcium Phosphate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Phosphate.	Approved
Camptothecin	The serum concentration of Camptothecin can be increased when it is combined with Felodipine.	Experimental
Canagliflozin	The serum concentration of Canagliflozin can be increased when it is combined with Felodipine.	Approved
Candesartan	Felodipine may increase the hypotensive activities of Candesartan.	Experimental
Candesartan cilexetil	Candesartan cilexetil may increase the hypotensive activities of Felodipine.	Approved
Candoxatril	Candoxatril may increase the hypotensive activities of Felodipine.	Experimental
Captopril	Felodipine may increase the hypotensive activities of Captopril.	Approved
Carbamazepine	The metabolism of Felodipine can be increased when combined with Carbamazepine.	Approved, Investigational
Carbaspirin calcium	The therapeutic efficacy of Felodipine can be decreased when used in combination with Carbaspirin calcium.	Experimental, Investigational
Carbetocin	The risk or severity of adverse effects can be increased when Carbetocin is combined with Felodipine.	Approved, Investigational
Carboxymethylcellulose	The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Felodipine.	Approved, Investigational
Carfilzomib	The serum concentration of Carfilzomib can be increased when it is combined with Felodipine.	Approved, Investigational
Caroxazone	Caroxazone may increase the hypotensive activities of Felodipine.	Withdrawn
Carprofen	The therapeutic efficacy of Felodipine can be decreased when used in combination with Carprofen.	Approved, Vet Approved, Withdrawn
Carteolol	Felodipine may increase the hypotensive activities of Carteolol.	Approved
Carvedilol	The risk or severity of hypotension can be increased when Carvedilol is combined with Felodipine.	Approved, Investigational
Castor oil	The therapeutic efficacy of Castor oil can be decreased when used in combination with Felodipine.	Approved, Investigational, Nutraceutical, Vet Approved
Celecoxib	The therapeutic efficacy of Felodipine can be decreased when used in combination with Celecoxib.	Approved, Investigational
Celiprolol	The serum concentration of Celiprolol can be increased when it is combined with Felodipine.	Approved, Investigational
Ceritinib	The serum concentration of Felodipine can be increased when it is combined with Ceritinib.	Approved
Cerivastatin	The metabolism of Cerivastatin can be decreased when combined with Felodipine.	Approved, Withdrawn
Cerliponase alfa	The serum concentration of Cerliponase alfa can be increased when it is combined with Felodipine.	Approved, Investigational
Chlorambucil	The serum concentration of Chlorambucil can be increased when it is combined with Felodipine.	Approved
Chloroquine	The serum concentration of Chloroquine can be increased when it is combined with Felodipine.	Approved, Investigational, Vet Approved
Chlorothiazide	Chlorothiazide may increase the hypotensive activities of Felodipine.	Approved, Vet Approved
Chlorpromazine	The risk or severity of hypotension can be increased when Chlorpromazine is combined with Felodipine.	Approved, Investigational, Vet Approved
Chlorthalidone	Chlorthalidone may increase the hypotensive activities of Felodipine.	Approved
Choline magnesium trisalicylate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Choline magnesium trisalicylate.	Approved
Cicletanine	Felodipine may increase the hypotensive activities of Cicletanine.	Investigational
Ciglitazone	The metabolism of Ciglitazone can be decreased when combined with Felodipine.	Experimental
Cilazapril	Felodipine may increase the hypotensive activities of Cilazapril.	Approved
Cilnidipine	The risk or severity of adverse effects can be increased when Cilnidipine is combined with Felodipine.	Approved, Investigational
Cimetidine	The serum concentration of Felodipine can be increased when it is combined with Cimetidine.	Approved, Investigational
Cimicoxib	The therapeutic efficacy of Felodipine can be decreased when used in combination with Cimicoxib.	Investigational
Ciprofloxacin	The serum concentration of Ciprofloxacin can be increased when it is combined with Felodipine.	Approved, Investigational
Cisatracurium	Felodipine may increase the neuromuscular blocking activities of Cisatracurium.	Approved
Cisplatin	The serum concentration of Cisplatin can be increased when it is combined with Felodipine.	Approved
Citalopram	The serum concentration of Citalopram can be increased when it is combined with Felodipine.	Approved
Clarithromycin	The metabolism of Felodipine can be decreased when combined with Clarithromycin.	Approved
Clevidipine	The risk or severity of adverse effects can be increased when Felodipine is combined with Clevidipine.	Approved, Investigational
Clobazam	The serum concentration of Clobazam can be increased when it is combined with Felodipine.	Approved, Illicit
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Felodipine.	Approved, Investigational
Clomipramine	The risk or severity of adverse effects can be increased when Clomipramine is combined with Felodipine.	Approved, Investigational, Vet Approved
Clonidine	The serum concentration of Clonidine can be increased when it is combined with Felodipine.	Approved
Clonixin	The therapeutic efficacy of Felodipine can be decreased when used in combination with Clonixin.	Approved
Clopidogrel	The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Felodipine.	Approved
Cloranolol	Felodipine may increase the hypotensive activities of Cloranolol.	Experimental
Clotrimazole	The metabolism of Felodipine can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The risk or severity of hypotension can be increased when Clozapine is combined with Felodipine.	Approved
Cobicistat	The metabolism of Felodipine can be decreased when combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Felodipine.	Approved, Investigational
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Felodipine.	Approved
Conivaptan	The serum concentration of Conivaptan can be increased when it is combined with Felodipine.	Approved, Investigational
Conjugated estrogens	The serum concentration of Conjugated estrogens can be increased when it is combined with Felodipine.	Approved
Copanlisib	The serum concentration of Copanlisib can be increased when it is combined with Felodipine.	Approved, Investigational
Crizotinib	The serum concentration of Crizotinib can be increased when it is combined with Felodipine.	Approved
Cryptenamine	Cryptenamine may increase the hypotensive activities of Felodipine.	Approved
Curcumin	The metabolism of Felodipine can be decreased when combined with Curcumin.	Approved, Investigational
Cyclopenthiazide	Felodipine may increase the hypotensive activities of Cyclopenthiazide.	Experimental
Cyclosporine	The metabolism of Felodipine can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyclothiazide	Cyclothiazide may increase the hypotensive activities of Felodipine.	Approved
Cytarabine	The serum concentration of Cytarabine can be increased when it is combined with Felodipine.	Approved, Investigational
Dabigatran etexilate	The serum concentration of Dabigatran etexilate can be increased when it is combined with Felodipine.	Approved
Dabrafenib	The serum concentration of Felodipine can be decreased when it is combined with Dabrafenib.	Approved, Investigational
Dactinomycin	The serum concentration of Dactinomycin can be increased when it is combined with Felodipine.	Approved, Investigational
Danazol	The metabolism of Felodipine can be decreased when combined with Danazol.	Approved
Danthron	The therapeutic efficacy of Danthron can be decreased when used in combination with Felodipine.	Approved, Investigational, Withdrawn
Dapagliflozin	The serum concentration of Dapagliflozin can be increased when it is combined with Felodipine.	Approved
Dapiprazole	The risk or severity of hypotension can be increased when Dapiprazole is combined with Felodipine.	Approved
Darunavir	The metabolism of Felodipine can be decreased when combined with Darunavir.	Approved
Dasabuvir	The serum concentration of Dasabuvir can be increased when it is combined with Felodipine.	Approved
Daunorubicin	The serum concentration of Daunorubicin can be increased when it is combined with Felodipine.	Approved
Debrisoquin	The serum concentration of Debrisoquin can be increased when it is combined with Felodipine.	Approved, Investigational
Deferasirox	The serum concentration of Felodipine can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delapril	Felodipine may increase the hypotensive activities of Delapril.	Investigational
Delavirdine	The metabolism of Felodipine can be decreased when combined with Delavirdine.	Approved
Deserpidine	Felodipine may increase the hypotensive activities of Deserpidine.	Approved
Desflurane	The risk or severity of adverse effects can be increased when Desflurane is combined with Felodipine.	Approved
Dexamethasone	The serum concentration of Dexamethasone can be increased when it is combined with Felodipine.	Approved, Investigational, Vet Approved
Dexibuprofen	The therapeutic efficacy of Felodipine can be decreased when used in combination with Dexibuprofen.	Approved, Investigational
Dexketoprofen	The therapeutic efficacy of Felodipine can be decreased when used in combination with Dexketoprofen.	Approved, Investigational
Dexmedetomidine	The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Felodipine.	Approved, Vet Approved
Dexniguldipine	Felodipine may increase the hypotensive activities of Dexniguldipine.	Experimental
Diazepam	The serum concentration of Diazepam can be increased when it is combined with Felodipine.	Approved, Illicit, Investigational, Vet Approved
Diazoxide	Diazoxide may increase the hypotensive activities of Felodipine.	Approved
Diclofenac	The therapeutic efficacy of Felodipine can be decreased when used in combination with Diclofenac.	Approved, Vet Approved
Diclofenamide	The risk or severity of adverse effects can be increased when Felodipine is combined with Diclofenamide.	Approved, Investigational
Diethylnorspermine	Felodipine may increase the hypotensive activities of Diethylnorspermine.	Investigational
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be increased when it is combined with Felodipine.	Approved, Investigational
Difenpiramide	The therapeutic efficacy of Felodipine can be decreased when used in combination with Difenpiramide.	Experimental
Diflunisal	The therapeutic efficacy of Felodipine can be decreased when used in combination with Diflunisal.	Approved, Investigational
Digitoxin	The serum concentration of Digitoxin can be increased when it is combined with Felodipine.	Approved, Investigational
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Felodipine.	Approved
Dihydralazine	Dihydralazine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Dihydroergotamine	The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Felodipine.	Approved, Investigational
Diltiazem	The metabolism of Felodipine can be decreased when combined with Diltiazem.	Approved, Investigational
Dinutuximab	The risk or severity of adverse effects can be increased when Felodipine is combined with Dinutuximab.	Approved, Investigational
Dipyridamole	Dipyridamole may increase the antihypertensive activities of Felodipine.	Approved
Docetaxel	The serum concentration of Docetaxel can be increased when it is combined with Felodipine.	Approved, Investigational
Docusate	The therapeutic efficacy of Docusate can be decreased when used in combination with Felodipine.	Approved
Dolutegravir	The serum concentration of Dolutegravir can be increased when it is combined with Felodipine.	Approved
Domperidone	The serum concentration of Domperidone can be increased when it is combined with Felodipine.	Approved, Investigational, Vet Approved
Dorzolamide	Dorzolamide may increase the hypotensive activities of Felodipine.	Approved
Doxacurium	Felodipine may increase the neuromuscular blocking activities of Doxacurium.	Approved
Doxazosin	The risk or severity of hypotension can be increased when Doxazosin is combined with Felodipine.	Approved
Doxepin	The risk or severity of hypotension can be increased when Doxepin is combined with Felodipine.	Approved, Investigational
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Felodipine.	Approved, Investigational
Doxycycline	The metabolism of Felodipine can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronedarone	The risk or severity of hypotension can be increased when Dronedarone is combined with Felodipine.	Approved
Droperidol	The risk or severity of hypotension can be increased when Droperidol is combined with Felodipine.	Approved, Vet Approved
Droxicam	The therapeutic efficacy of Felodipine can be decreased when used in combination with Droxicam.	Withdrawn
Duloxetine	Felodipine may increase the orthostatic hypotensive activities of Duloxetine.	Approved
Econazole	The therapeutic efficacy of Econazole can be increased when used in combination with Felodipine.	Approved
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Felodipine.	Approved
Efavirenz	The serum concentration of Felodipine can be decreased when it is combined with Efavirenz.	Approved, Investigational
Efinaconazole	The therapeutic efficacy of Efinaconazole can be increased when used in combination with Felodipine.	Approved
Efonidipine	Felodipine may increase the hypotensive activities of Efonidipine.	Approved, Investigational
Elagolix	The metabolism of Elagolix can be decreased when combined with Felodipine.	Approved, Investigational
Elbasvir	The serum concentration of Elbasvir can be increased when it is combined with Felodipine.	Approved
Eletriptan	The serum concentration of Eletriptan can be increased when it is combined with Felodipine.	Approved, Investigational
Empagliflozin	The risk or severity of adverse effects can be increased when Felodipine is combined with Empagliflozin.	Approved
Enalapril	Enalapril may increase the hypotensive activities of Felodipine.	Approved, Vet Approved
Enalaprilat	Felodipine may increase the hypotensive activities of Enalaprilat.	Approved
Endralazine	Endralazine may increase the hypotensive activities of Felodipine.	Experimental
Enzalutamide	The serum concentration of Enzalutamide can be increased when it is combined with Felodipine.	Approved
Epanolol	Felodipine may increase the hypotensive activities of Epanolol.	Experimental
Epinastine	The serum concentration of Epinastine can be increased when it is combined with Felodipine.	Approved, Investigational
Epirizole	The therapeutic efficacy of Felodipine can be decreased when used in combination with Epirizole.	Approved
Eplerenone	The risk or severity of adverse effects can be increased when Eplerenone is combined with Felodipine.	Approved
Epoprostenol	Epoprostenol may increase the hypotensive activities of Felodipine.	Approved
Eprosartan	Eprosartan may increase the hypotensive activities of Felodipine.	Approved
Ergotamine	The risk or severity of hypotension can be increased when Ergotamine is combined with Felodipine.	Approved
Erlotinib	The serum concentration of Erlotinib can be increased when it is combined with Felodipine.	Approved, Investigational
Ertugliflozin	The serum concentration of Ertugliflozin can be increased when it is combined with Felodipine.	Approved, Investigational
Erythromycin	The serum concentration of Erythromycin can be increased when it is combined with Felodipine.	Approved, Investigational, Vet Approved
Esatenolol	Felodipine may increase the hypotensive activities of Esatenolol.	Experimental
Esmolol	Felodipine may increase the hypotensive activities of Esmolol.	Approved
Estradiol	The serum concentration of Estradiol can be increased when it is combined with Felodipine.	Approved, Investigational, Vet Approved
Estradiol acetate	The serum concentration of Estradiol acetate can be increased when it is combined with Felodipine.	Approved, Investigational, Vet Approved
Estradiol benzoate	The serum concentration of Estradiol benzoate can be increased when it is combined with Felodipine.	Approved, Investigational, Vet Approved
Estradiol cypionate	The serum concentration of Estradiol cypionate can be increased when it is combined with Felodipine.	Approved, Investigational, Vet Approved
Estradiol dienanthate	The serum concentration of Estradiol dienanthate can be increased when it is combined with Felodipine.	Approved, Investigational, Vet Approved
Estradiol valerate	The serum concentration of Estradiol valerate can be increased when it is combined with Felodipine.	Approved, Investigational, Vet Approved
Estriol	The serum concentration of Estriol can be increased when it is combined with Felodipine.	Approved, Investigational, Vet Approved
Estrone	The serum concentration of Estrone can be increased when it is combined with Felodipine.	Approved
Etacrynic acid	The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Felodipine.	Approved, Investigational
Ethenzamide	The therapeutic efficacy of Felodipine can be decreased when used in combination with Ethenzamide.	Experimental
Ethinyl Estradiol	The serum concentration of Ethinyl Estradiol can be increased when it is combined with Felodipine.	Approved
Etodolac	The therapeutic efficacy of Felodipine can be decreased when used in combination with Etodolac.	Approved, Investigational, Vet Approved
Etofenamate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Etofenamate.	Approved, Investigational
Etoposide	The serum concentration of Etoposide can be increased when it is combined with Felodipine.	Approved
Etoricoxib	The therapeutic efficacy of Felodipine can be decreased when used in combination with Etoricoxib.	Approved, Investigational
Etravirine	The serum concentration of Felodipine can be decreased when it is combined with Etravirine.	Approved
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Felodipine.	Approved
Ezetimibe	The serum concentration of Ezetimibe can be increased when it is combined with Felodipine.	Approved
Felbinac	The therapeutic efficacy of Felodipine can be decreased when used in combination with Felbinac.	Experimental
Fenbufen	The therapeutic efficacy of Felodipine can be decreased when used in combination with Fenbufen.	Approved
Fenoldopam	Fenoldopam may increase the hypotensive activities of Felodipine.	Approved
Fenoprofen	The therapeutic efficacy of Felodipine can be decreased when used in combination with Fenoprofen.	Approved
Fentiazac	The therapeutic efficacy of Felodipine can be decreased when used in combination with Fentiazac.	Experimental
Fenticonazole	The therapeutic efficacy of Fenticonazole can be increased when used in combination with Felodipine.	Experimental
Feprazone	The therapeutic efficacy of Felodipine can be decreased when used in combination with Feprazone.	Experimental
Ferulic acid	Felodipine may increase the hypotensive activities of Ferulic acid.	Experimental
Fesoterodine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Felodipine.	Approved
Fexofenadine	The serum concentration of Fexofenadine can be increased when it is combined with Felodipine.	Approved, Investigational
Fidaxomicin	The serum concentration of Fidaxomicin can be increased when it is combined with Felodipine.	Approved
Fimasartan	The risk or severity of adverse effects can be increased when Fimasartan is combined with Felodipine.	Approved, Investigational
Firocoxib	The therapeutic efficacy of Felodipine can be decreased when used in combination with Firocoxib.	Experimental, Vet Approved
Floctafenine	The therapeutic efficacy of Felodipine can be decreased when used in combination with Floctafenine.	Approved, Withdrawn
Fluciclovine (18F)	The serum concentration of Fluciclovine (18F) can be increased when it is combined with Felodipine.	Approved
Fluconazole	The serum concentration of Felodipine can be increased when it is combined with Fluconazole.	Approved, Investigational
Flunixin	The therapeutic efficacy of Felodipine can be decreased when used in combination with Flunixin.	Vet Approved
Flunoxaprofen	The therapeutic efficacy of Felodipine can be decreased when used in combination with Flunoxaprofen.	Experimental
Flupentixol	The risk or severity of hypotension can be increased when Flupentixol is combined with Felodipine.	Approved, Investigational, Withdrawn
Flurbiprofen	The therapeutic efficacy of Felodipine can be decreased when used in combination with Flurbiprofen.	Approved, Investigational
Fluticasone	The serum concentration of Fluticasone can be increased when it is combined with Felodipine.	Approved, Experimental, Investigational
Fluticasone furoate	The serum concentration of Fluticasone furoate can be increased when it is combined with Felodipine.	Approved
Fluticasone propionate	The serum concentration of Fluticasone propionate can be increased when it is combined with Felodipine.	Approved
Flutrimazole	The therapeutic efficacy of Flutrimazole can be increased when used in combination with Felodipine.	Experimental
Fluvoxamine	The metabolism of Felodipine can be decreased when combined with Fluvoxamine.	Approved, Investigational
Fosamprenavir	The metabolism of Felodipine can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Felodipine can be increased when it is combined with Fosaprepitant.	Approved
Fosinopril	Fosinopril may increase the hypotensive activities of Felodipine.	Approved
Fosinoprilat	Felodipine may increase the hypotensive activities of Fosinoprilat.	Experimental
Fosphenytoin	The serum concentration of Fosphenytoin can be increased when it is combined with Felodipine.	Approved, Investigational
Fostamatinib	Fostamatinib may increase the antihypertensive activities of Felodipine.	Approved, Investigational
Furazolidone	Furazolidone may increase the hypotensive activities of Felodipine.	Approved, Investigational, Vet Approved
Furosemide	The risk or severity of adverse effects can be increased when Furosemide is combined with Felodipine.	Approved, Vet Approved
Fusidic Acid	The serum concentration of Felodipine can be increased when it is combined with Fusidic Acid.	Approved, Investigational
Gallamine	Felodipine may increase the neuromuscular blocking activities of Gallamine.	Experimental
Gallamine Triethiodide	Felodipine may increase the neuromuscular blocking activities of Gallamine Triethiodide.	Approved
Gefitinib	The serum concentration of Gefitinib can be increased when it is combined with Felodipine.	Approved, Investigational
Glecaprevir	The serum concentration of Glecaprevir can be increased when it is combined with Felodipine.	Approved, Investigational
Glycerin	The therapeutic efficacy of Glycerin can be decreased when used in combination with Felodipine.	Approved, Investigational
Gramicidin D	The serum concentration of Gramicidin D can be increased when it is combined with Felodipine.	Approved
Grazoprevir	The serum concentration of Grazoprevir can be increased when it is combined with Felodipine.	Approved
Grepafloxacin	The serum concentration of Grepafloxacin can be increased when it is combined with Felodipine.	Approved, Investigational, Withdrawn
Guacetisal	The therapeutic efficacy of Felodipine can be decreased when used in combination with Guacetisal.	Experimental
Guanabenz	Guanabenz may increase the hypotensive activities of Felodipine.	Approved, Investigational
Guanadrel	Guanadrel may increase the hypotensive activities of Felodipine.	Approved
Guanazodine	Felodipine may increase the hypotensive activities of Guanazodine.	Experimental
Guanethidine	Felodipine may increase the hypotensive activities of Guanethidine.	Approved
Guanfacine	Guanfacine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Guanoclor	Felodipine may increase the hypotensive activities of Guanoclor.	Experimental
Guanoxabenz	Felodipine may increase the hypotensive activities of Guanoxabenz.	Experimental
Guanoxan	Felodipine may increase the hypotensive activities of Guanoxan.	Experimental
Halothane	The risk or severity of adverse effects can be increased when Halothane is combined with Felodipine.	Approved, Vet Approved
Harmaline	Harmaline may increase the hypotensive activities of Felodipine.	Experimental
Hexamethonium	Felodipine may increase the hypotensive activities of Hexamethonium.	Experimental
Hexobarbital	Hexobarbital may increase the hypotensive activities of Felodipine.	Approved
Hydracarbazine	Hydracarbazine may increase the hypotensive activities of Felodipine.	Experimental
Hydralazine	Hydralazine may increase the hypotensive activities of Felodipine.	Approved
Hydrochlorothiazide	Hydrochlorothiazide may increase the hypotensive activities of Felodipine.	Approved, Vet Approved
Hydrocodone	The serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Felodipine resulting in a loss in efficacy.	Approved, Illicit
Hydrocortisone	The serum concentration of Hydrocortisone can be increased when it is combined with Felodipine.	Approved, Vet Approved
Hydroflumethiazide	Hydroflumethiazide may increase the hypotensive activities of Felodipine.	Approved, Investigational
Hydroxyurea	The serum concentration of Hydroxyurea can be increased when it is combined with Felodipine.	Approved
Ibuprofen	The therapeutic efficacy of Felodipine can be decreased when used in combination with Ibuprofen.	Approved
Ibuproxam	The therapeutic efficacy of Felodipine can be decreased when used in combination with Ibuproxam.	Withdrawn
Icosapent	The therapeutic efficacy of Felodipine can be decreased when used in combination with Icosapent.	Approved, Nutraceutical
Idelalisib	The serum concentration of Felodipine can be increased when it is combined with Idelalisib.	Approved
Iloperidone	The risk or severity of hypotension can be increased when Iloperidone is combined with Felodipine.	Approved
Iloprost	Iloprost may increase the hypotensive activities of Felodipine.	Approved, Investigational
Imatinib	The serum concentration of Imatinib can be increased when it is combined with Felodipine.	Approved
Imidapril	Felodipine may increase the hypotensive activities of Imidapril.	Investigational
Imidazole salicylate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Imidazole salicylate.	Experimental
Imipramine	The risk or severity of hypotension can be increased when Imipramine is combined with Felodipine.	Approved
Indacaterol	The serum concentration of Indacaterol can be increased when it is combined with Felodipine.	Approved
Indapamide	Indapamide may increase the hypotensive activities of Felodipine.	Approved
Indenolol	Felodipine may increase the hypotensive activities of Indenolol.	Withdrawn
Indinavir	The metabolism of Felodipine can be decreased when combined with Indinavir.	Approved
Indobufen	The therapeutic efficacy of Felodipine can be decreased when used in combination with Indobufen.	Investigational
Indomethacin	The therapeutic efficacy of Felodipine can be decreased when used in combination with Indomethacin.	Approved, Investigational
Indoprofen	The therapeutic efficacy of Felodipine can be decreased when used in combination with Indoprofen.	Withdrawn
Indoramin	The risk or severity of hypotension can be increased when Indoramin is combined with Felodipine.	Withdrawn
Inotuzumab ozogamicin	The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Felodipine.	Approved, Investigational
Iproniazid	Iproniazid may increase the hypotensive activities of Felodipine.	Withdrawn
Irbesartan	Felodipine may increase the hypotensive activities of Irbesartan.	Approved, Investigational
Irinotecan	The serum concentration of Irinotecan can be increased when it is combined with Felodipine.	Approved, Investigational
Isavuconazole	The serum concentration of Felodipine can be increased when it is combined with Isavuconazole.	Approved, Investigational
Isavuconazonium	The metabolism of Felodipine can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isocarboxazid	Isocarboxazid may increase the hypotensive activities of Felodipine.	Approved
Isoconazole	The therapeutic efficacy of Isoconazole can be increased when used in combination with Felodipine.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Isoflurane is combined with Felodipine.	Approved, Vet Approved
Isoniazid	The metabolism of Felodipine can be decreased when combined with Isoniazid.	Approved, Investigational
Isosorbide Dinitrate	The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Felodipine.	Approved, Investigational
Isosorbide Mononitrate	The risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Felodipine.	Approved
Isoxicam	The therapeutic efficacy of Felodipine can be decreased when used in combination with Isoxicam.	Withdrawn
Isoxsuprine	The risk or severity of adverse effects can be increased when Felodipine is combined with Isoxsuprine.	Approved, Withdrawn
Isradipine	Isradipine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Itraconazole	The serum concentration of Felodipine can be increased when it is combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Felodipine can be increased when it is combined with Ivacaftor.	Approved
Ivermectin	The serum concentration of Ivermectin can be increased when it is combined with Felodipine.	Approved, Investigational, Vet Approved
Ivosidenib	The serum concentration of Ivosidenib can be increased when it is combined with Felodipine.	Approved, Investigational
Kebuzone	The therapeutic efficacy of Felodipine can be decreased when used in combination with Kebuzone.	Experimental
Ketanserin	Ketanserin may increase the hypotensive activities of Felodipine.	Investigational
Ketazolam	The serum concentration of Ketazolam can be increased when it is combined with Felodipine.	Approved
Ketoconazole	The serum concentration of Felodipine can be increased when it is combined with Ketoconazole.	Approved, Investigational
Ketoprofen	The therapeutic efficacy of Felodipine can be decreased when used in combination with Ketoprofen.	Approved, Vet Approved
Ketorolac	The therapeutic efficacy of Felodipine can be decreased when used in combination with Ketorolac.	Approved
Labetalol	The risk or severity of hypotension can be increased when Labetalol is combined with Felodipine.	Approved
Lacidipine	Felodipine may increase the hypotensive activities of Lacidipine.	Approved, Investigational
Lactitol	The therapeutic efficacy of Lactitol can be decreased when used in combination with Felodipine.	Investigational
Lactulose	The therapeutic efficacy of Lactulose can be decreased when used in combination with Felodipine.	Approved
Lamivudine	The serum concentration of Lamivudine can be increased when it is combined with Felodipine.	Approved, Investigational
Lamotrigine	The serum concentration of Lamotrigine can be increased when it is combined with Felodipine.	Approved, Investigational
Lansoprazole	The serum concentration of Lansoprazole can be increased when it is combined with Felodipine.	Approved, Investigational
Lapatinib	The metabolism of Lapatinib can be decreased when combined with Felodipine.	Approved, Investigational
Latanoprost	Latanoprost may increase the hypotensive activities of Felodipine.	Approved, Investigational
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Felodipine.	Approved
Lenalidomide	The serum concentration of Lenalidomide can be increased when it is combined with Felodipine.	Approved
Lenvatinib	The serum concentration of Lenvatinib can be increased when it is combined with Felodipine.	Approved, Investigational
Lercanidipine	Lercanidipine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Letermovir	The serum concentration of Letermovir can be increased when it is combined with Felodipine.	Approved, Investigational
Levetiracetam	The serum concentration of Levetiracetam can be increased when it is combined with Felodipine.	Approved, Investigational
Levobunolol	The risk or severity of adverse effects can be increased when Felodipine is combined with Levobunolol.	Approved
Levobupivacaine	The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Felodipine.	Approved, Investigational
Levodopa	Felodipine may increase the orthostatic hypotensive activities of Levodopa.	Approved
Levofloxacin	The serum concentration of Levofloxacin can be increased when it is combined with Felodipine.	Approved, Investigational
Levomilnacipran	The serum concentration of Levomilnacipran can be increased when it is combined with Felodipine.	Approved, Investigational
Levosimendan	The risk or severity of adverse effects can be increased when Levosimendan is combined with Felodipine.	Approved, Investigational
Linaclotide	The therapeutic efficacy of Linaclotide can be decreased when used in combination with Felodipine.	Approved
Linagliptin	The serum concentration of Linagliptin can be increased when it is combined with Felodipine.	Approved
Linezolid	Linezolid may increase the hypotensive activities of Felodipine.	Approved, Investigational
Linsidomine	Felodipine may increase the hypotensive activities of Linsidomine.	Experimental
Lisinopril	Lisinopril may increase the hypotensive activities of Felodipine.	Approved, Investigational
Lobeglitazone	The metabolism of Lobeglitazone can be decreased when combined with Felodipine.	Approved, Investigational
Lofexidine	Felodipine may increase the hypotensive activities of Lofexidine.	Approved, Investigational
Lonazolac	The therapeutic efficacy of Felodipine can be decreased when used in combination with Lonazolac.	Experimental
Loperamide	The serum concentration of Loperamide can be increased when it is combined with Felodipine.	Approved
Lopinavir	The metabolism of Felodipine can be decreased when combined with Lopinavir.	Approved
Lornoxicam	The therapeutic efficacy of Felodipine can be decreased when used in combination with Lornoxicam.	Approved, Investigational
Lorpiprazole	The serum concentration of Felodipine can be increased when it is combined with Lorpiprazole.	Approved
Losartan	The serum concentration of Losartan can be increased when it is combined with Felodipine.	Approved
Lovastatin	The serum concentration of Lovastatin can be increased when it is combined with Felodipine.	Approved, Investigational
Loxoprofen	The therapeutic efficacy of Felodipine can be decreased when used in combination with Loxoprofen.	Approved, Investigational
Lubiprostone	The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Felodipine.	Approved, Investigational
Luliconazole	The serum concentration of Felodipine can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The metabolism of Felodipine can be increased when combined with Lumacaftor.	Approved
Lumiracoxib	The therapeutic efficacy of Felodipine can be decreased when used in combination with Lumiracoxib.	Approved, Investigational
Lusutrombopag	The serum concentration of Lusutrombopag can be increased when it is combined with Felodipine.	Approved, Investigational
Macitentan	Felodipine may increase the hypotensive activities of Macitentan.	Approved
Magnesium carbonate	The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Felodipine.	Approved, Investigational
Magnesium citrate	The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Felodipine.	Approved
Magnesium hydroxide	The risk or severity of hypotension and neuromuscular blockade can be increased when Felodipine is combined with Magnesium hydroxide.	Approved, Investigational
Magnesium oxide	The risk or severity of hypotension and neuromuscular blockade can be increased when Felodipine is combined with Magnesium oxide.	Approved
Magnesium peroxide	The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Felodipine.	Experimental
Magnesium salicylate	The risk or severity of hypotension and neuromuscular blockade can be increased when Felodipine is combined with Magnesium salicylate.	Approved
Magnesium sulfate	The risk or severity of hypotension and neuromuscular blockade can be increased when Felodipine is combined with Magnesium sulfate.	Approved, Investigational, Vet Approved
Manidipine	Felodipine may increase the hypotensive activities of Manidipine.	Approved, Investigational
Mannitol	The therapeutic efficacy of Mannitol can be decreased when used in combination with Felodipine.	Approved, Investigational
Mebanazine	Mebanazine may increase the hypotensive activities of Felodipine.	Withdrawn
Mecamylamine	Mecamylamine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Meclofenamic acid	The therapeutic efficacy of Felodipine can be decreased when used in combination with Meclofenamic acid.	Approved, Vet Approved
Mefenamic acid	The therapeutic efficacy of Felodipine can be decreased when used in combination with Mefenamic acid.	Approved
Mefloquine	The serum concentration of Mefloquine can be increased when it is combined with Felodipine.	Approved, Investigational
Melatonin	Melatonin may decrease the antihypertensive activities of Felodipine.	Approved, Nutraceutical, Vet Approved
Meloxicam	The therapeutic efficacy of Felodipine can be decreased when used in combination with Meloxicam.	Approved, Vet Approved
Melphalan	The serum concentration of Melphalan can be increased when it is combined with Felodipine.	Approved
Mesalazine	The therapeutic efficacy of Felodipine can be decreased when used in combination with Mesalazine.	Approved
Metamizole	The therapeutic efficacy of Felodipine can be decreased when used in combination with Metamizole.	Approved, Investigational, Withdrawn
Methazolamide	The risk or severity of adverse effects can be increased when Methazolamide is combined with Felodipine.	Approved
Methohexital	Methohexital may increase the hypotensive activities of Felodipine.	Approved
Methoserpidine	Felodipine may increase the hypotensive activities of Methoserpidine.	Experimental
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Felodipine.	Approved
Methotrimeprazine	The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Felodipine.	Approved, Investigational
Methyclothiazide	The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Felodipine.	Approved
Methyl cellulose	The therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Felodipine.	Approved
Methyldopa	Methyldopa may increase the hypotensive activities of Felodipine.	Approved
Methylene blue	Methylene blue may increase the hypotensive activities of Felodipine.	Approved, Investigational
Methylphenidate	Methylphenidate may decrease the antihypertensive activities of Felodipine.	Approved, Investigational
Methylphenobarbital	Methylphenobarbital may increase the hypotensive activities of Felodipine.	Approved
Methylprednisolone	The serum concentration of Methylprednisolone can be increased when it is combined with Felodipine.	Approved, Vet Approved
Metipranolol	Felodipine may increase the hypotensive activities of Metipranolol.	Approved
Metocurine	Felodipine may increase the neuromuscular blocking activities of Metocurine.	Approved
Metocurine Iodide	Felodipine may increase the neuromuscular blocking activities of Metocurine Iodide.	Approved, Withdrawn
Metolazone	Metolazone may increase the hypotensive activities of Felodipine.	Approved
Metoprolol	The serum concentration of Metoprolol can be increased when it is combined with Felodipine.	Approved, Investigational
Metyrosine	Felodipine may increase the hypotensive activities of Metyrosine.	Approved
Mibefradil	The metabolism of Felodipine can be decreased when combined with Mibefradil.	Investigational, Withdrawn
Miconazole	The metabolism of Felodipine can be decreased when combined with Miconazole.	Approved, Investigational, Vet Approved
Mifepristone	The serum concentration of Felodipine can be increased when it is combined with Mifepristone.	Approved, Investigational
Minaprine	Minaprine may increase the hypotensive activities of Felodipine.	Approved
Mineral oil	The therapeutic efficacy of Mineral oil can be decreased when used in combination with Felodipine.	Approved, Vet Approved
Minoxidil	Minoxidil may increase the hypotensive activities of Felodipine.	Approved, Investigational
Mirabegron	The serum concentration of Mirabegron can be increased when it is combined with Felodipine.	Approved
Mirodenafil	Mirodenafil may increase the antihypertensive activities of Felodipine.	Investigational
Mitomycin	The serum concentration of Mitomycin can be increased when it is combined with Felodipine.	Approved
Mitotane	The serum concentration of Felodipine can be decreased when it is combined with Mitotane.	Approved
Mitoxantrone	The serum concentration of Mitoxantrone can be increased when it is combined with Felodipine.	Approved, Investigational
Mivacurium	Felodipine may increase the neuromuscular blocking activities of Mivacurium.	Approved
Moclobemide	Moclobemide may increase the hypotensive activities of Felodipine.	Approved, Investigational
Modafinil	The serum concentration of Felodipine can be decreased when it is combined with Modafinil.	Approved, Investigational
Moexipril	Moexipril may increase the hypotensive activities of Felodipine.	Approved
Mofebutazone	The therapeutic efficacy of Felodipine can be decreased when used in combination with Mofebutazone.	Experimental
Molsidomine	Molsidomine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Morniflumate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Morniflumate.	Approved
Morphine	The serum concentration of Morphine can be increased when it is combined with Felodipine.	Approved, Investigational
Moxidectin	The serum concentration of Moxidectin can be increased when it is combined with Felodipine.	Approved, Investigational, Vet Approved
Moxonidine	Moxonidine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Muzolimine	Felodipine may increase the hypotensive activities of Muzolimine.	Experimental
Mycophenolate mofetil	The serum concentration of Mycophenolate mofetil can be increased when it is combined with Felodipine.	Approved, Investigational
Nabilone	The risk or severity of adverse effects can be increased when Nabilone is combined with Felodipine.	Approved, Investigational
Nabumetone	The therapeutic efficacy of Felodipine can be decreased when used in combination with Nabumetone.	Approved
Nadolol	The serum concentration of Nadolol can be increased when it is combined with Felodipine.	Approved
Nafcillin	The therapeutic efficacy of Felodipine can be decreased when used in combination with Nafcillin.	Approved, Investigational
Naftopidil	Felodipine may increase the hypotensive activities of Naftopidil.	Investigational
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Felodipine.	Approved
Naloxone	The metabolism of Felodipine can be decreased when combined with Naloxone.	Approved, Vet Approved
Naproxen	The therapeutic efficacy of Felodipine can be decreased when used in combination with Naproxen.	Approved, Vet Approved
Nebivolol	Felodipine may increase the hypotensive activities of Nebivolol.	Approved, Investigational
Nefazodone	The risk or severity of hypotension can be increased when Nefazodone is combined with Felodipine.	Approved, Withdrawn
Nelfinavir	The metabolism of Felodipine can be decreased when combined with Nelfinavir.	Approved
Neostigmine	The serum concentration of Neostigmine can be increased when it is combined with Felodipine.	Approved, Vet Approved
Nepafenac	The therapeutic efficacy of Felodipine can be decreased when used in combination with Nepafenac.	Approved, Investigational
Nesiritide	The risk or severity of adverse effects can be increased when Felodipine is combined with Nesiritide.	Approved, Investigational
Netoglitazone	The metabolism of Netoglitazone can be decreased when combined with Felodipine.	Experimental
Netupitant	The serum concentration of Felodipine can be increased when it is combined with Netupitant.	Approved, Investigational
Nevirapine	The metabolism of Felodipine can be increased when combined with Nevirapine.	Approved
Nialamide	Nialamide may increase the hypotensive activities of Felodipine.	Withdrawn
Nicardipine	The risk or severity of hypotension can be increased when Nicardipine is combined with Felodipine.	Approved, Investigational
Nicergoline	The risk or severity of hypotension can be increased when Nicergoline is combined with Felodipine.	Approved, Investigational
Nicorandil	Nicorandil may increase the hypotensive activities of Felodipine.	Approved, Investigational
Nifedipine	The serum concentration of Nifedipine can be increased when it is combined with Felodipine.	Approved
Nifenazone	The therapeutic efficacy of Felodipine can be decreased when used in combination with Nifenazone.	Experimental
Niflumic Acid	The therapeutic efficacy of Felodipine can be decreased when used in combination with Niflumic Acid.	Approved
Niguldipine	The risk or severity of hypotension can be increased when Niguldipine is combined with Felodipine.	Experimental
Nilotinib	The metabolism of Felodipine can be decreased when combined with Nilotinib.	Approved, Investigational
Nilvadipine	Felodipine may increase the hypotensive activities of Nilvadipine.	Approved, Investigational
Nimesulide	The therapeutic efficacy of Felodipine can be decreased when used in combination with Nimesulide.	Approved, Investigational, Withdrawn
Nimodipine	Nimodipine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Felodipine.	Approved
Nisoldipine	Nisoldipine may increase the hypotensive activities of Felodipine.	Approved
Nitrendipine	Felodipine may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Nitric Oxide	The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Felodipine.	Approved
Nitroaspirin	The therapeutic efficacy of Felodipine can be decreased when used in combination with Nitroaspirin.	Investigational
Nitroglycerin	The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Felodipine.	Approved, Investigational
Nitroprusside	Felodipine may increase the hypotensive activities of Nitroprusside.	Approved, Investigational
Nitrous acid	The risk or severity of adverse effects can be increased when Nitrous acid is combined with Felodipine.	Approved, Investigational
Nizatidine	The serum concentration of Nizatidine can be increased when it is combined with Felodipine.	Approved
Nortriptyline	The risk or severity of hypotension can be increased when Nortriptyline is combined with Felodipine.	Approved
NS-398	The therapeutic efficacy of Felodipine can be decreased when used in combination with NS-398.	Experimental
Obinutuzumab	Felodipine may increase the hypotensive activities of Obinutuzumab.	Approved, Investigational
Octamoxin	Octamoxin may increase the hypotensive activities of Felodipine.	Withdrawn
Octreotide	The serum concentration of Octreotide can be increased when it is combined with Felodipine.	Approved, Investigational
Odanacatib	The serum concentration of Odanacatib can be increased when it is combined with Felodipine.	Investigational
Olanzapine	The risk or severity of hypotension can be increased when Olanzapine is combined with Felodipine.	Approved, Investigational
Olaparib	The metabolism of Felodipine can be decreased when combined with Olaparib.	Approved
Olmesartan	Olmesartan may increase the hypotensive activities of Felodipine.	Approved, Investigational
Olsalazine	The therapeutic efficacy of Felodipine can be decreased when used in combination with Olsalazine.	Approved
Omapatrilat	Omapatrilat may increase the hypotensive activities of Felodipine.	Investigational
Ombitasvir	The serum concentration of Ombitasvir can be increased when it is combined with Felodipine.	Approved, Investigational
Omeprazole	The serum concentration of Omeprazole can be increased when it is combined with Felodipine.	Approved, Investigational, Vet Approved
Omoconazole	The therapeutic efficacy of Omoconazole can be increased when used in combination with Felodipine.	Experimental
Ondansetron	The serum concentration of Ondansetron can be increased when it is combined with Felodipine.	Approved
Oxaprozin	The therapeutic efficacy of Felodipine can be decreased when used in combination with Oxaprozin.	Approved
Oxiconazole	The therapeutic efficacy of Oxiconazole can be increased when used in combination with Felodipine.	Approved
Oxprenolol	Felodipine may increase the hypotensive activities of Oxprenolol.	Approved
Oxyphenbutazone	The therapeutic efficacy of Felodipine can be decreased when used in combination with Oxyphenbutazone.	Approved, Withdrawn
Oxyphenisatin	The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Felodipine.	Investigational, Withdrawn
Paclitaxel	The metabolism of Paclitaxel can be decreased when combined with Felodipine.	Approved, Vet Approved
Palbociclib	The serum concentration of Felodipine can be increased when it is combined with Palbociclib.	Approved, Investigational
Paliperidone	The risk or severity of hypotension can be increased when Paliperidone is combined with Felodipine.	Approved
Pancuronium	Felodipine may increase the neuromuscular blocking activities of Pancuronium.	Approved
Panobinostat	The serum concentration of Panobinostat can be increased when it is combined with Felodipine.	Approved, Investigational
Pantoprazole	The serum concentration of Pantoprazole can be increased when it is combined with Felodipine.	Approved
Papaverine	The risk or severity of adverse effects can be increased when Felodipine is combined with Papaverine.	Approved, Investigational
Parecoxib	The therapeutic efficacy of Felodipine can be decreased when used in combination with Parecoxib.	Approved
Pargyline	Pargyline may increase the hypotensive activities of Felodipine.	Approved
Paritaprevir	The serum concentration of Paritaprevir can be increased when it is combined with Felodipine.	Approved, Investigational
Patent Blue	The therapeutic efficacy of Felodipine can be decreased when used in combination with Patent Blue.	Approved
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Felodipine.	Approved
Penbutolol	Felodipine may increase the hypotensive activities of Penbutolol.	Approved, Investigational
Pentaerithrityl	The therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Felodipine.	Experimental
Pentazocine	The serum concentration of Pentazocine can be increased when it is combined with Felodipine.	Approved, Vet Approved
Pentobarbital	Pentobarbital may increase the hypotensive activities of Felodipine.	Approved, Investigational, Vet Approved
Pentolinium	Felodipine may increase the hypotensive activities of Pentolinium.	Approved
Perindopril	Perindopril may increase the hypotensive activities of Felodipine.	Approved
Perindoprilat	Felodipine may increase the hypotensive activities of Perindoprilat.	Experimental
Phenelzine	Phenelzine may increase the hypotensive activities of Felodipine.	Approved
Pheniprazine	Pheniprazine may increase the hypotensive activities of Felodipine.	Withdrawn
Phenobarbital	Phenobarbital may increase the hypotensive activities of Felodipine.	Approved, Investigational
Phenolphthalein	The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Felodipine.	Approved, Withdrawn
Phenothiazine	The serum concentration of Phenothiazine can be increased when it is combined with Felodipine.	Vet Approved
Phenoxybenzamine	The risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Felodipine.	Approved
Phenoxypropazine	Phenoxypropazine may increase the hypotensive activities of Felodipine.	Withdrawn
Phenprocoumon	The metabolism of Phenprocoumon can be decreased when combined with Felodipine.	Approved, Investigational
Phentolamine	The risk or severity of hypotension can be increased when Phentolamine is combined with Felodipine.	Approved
Phenylbutazone	The therapeutic efficacy of Felodipine can be decreased when used in combination with Phenylbutazone.	Approved, Vet Approved
Phenytoin	The serum concentration of Phenytoin can be increased when it is combined with Felodipine.	Approved, Vet Approved
Pibrentasvir	The serum concentration of Pibrentasvir can be increased when it is combined with Felodipine.	Approved, Investigational
Picosulfuric acid	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Felodipine.	Approved
Pinacidil	Pinacidil may increase the hypotensive activities of Felodipine.	Approved
Pindolol	Felodipine may increase the hypotensive activities of Pindolol.	Approved, Investigational
Pioglitazone	The serum concentration of Pioglitazone can be increased when it is combined with Felodipine.	Approved, Investigational
Pipamperone	The risk or severity of adverse effects can be increased when Pipamperone is combined with Felodipine.	Approved, Investigational
Pipecuronium	Felodipine may increase the neuromuscular blocking activities of Pipecuronium.	Approved
Pirlindole	Pirlindole may increase the hypotensive activities of Felodipine.	Approved
Piroxicam	The therapeutic efficacy of Felodipine can be decreased when used in combination with Piroxicam.	Approved, Investigational
Pirprofen	The therapeutic efficacy of Felodipine can be decreased when used in combination with Pirprofen.	Experimental
Pitavastatin	The serum concentration of Pitavastatin can be increased when it is combined with Felodipine.	Approved
Pitolisant	The serum concentration of Pitolisant can be increased when it is combined with Felodipine.	Approved, Investigational
Pivhydrazine	Pivhydrazine may increase the hypotensive activities of Felodipine.	Withdrawn
Pizotifen	The risk or severity of hypotension can be increased when Pizotifen is combined with Felodipine.	Approved
Plantago seed	The therapeutic efficacy of Plantago seed can be decreased when used in combination with Felodipine.	Approved, Investigational
Plecanatide	The therapeutic efficacy of Plecanatide can be decreased when used in combination with Felodipine.	Approved, Investigational
Polycarbophil	The therapeutic efficacy of Polycarbophil can be decreased when used in combination with Felodipine.	Approved
Polyethylene glycol	The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Felodipine.	Approved, Vet Approved
Polythiazide	Felodipine may increase the hypotensive activities of Polythiazide.	Approved
Pomalidomide	The serum concentration of Pomalidomide can be increased when it is combined with Felodipine.	Approved
Ponatinib	The serum concentration of Ponatinib can be increased when it is combined with Felodipine.	Approved, Investigational
Posaconazole	The metabolism of Felodipine can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Potassium acetate	The therapeutic efficacy of Potassium acetate can be decreased when used in combination with Felodipine.	Approved, Investigational
Practolol	Felodipine may increase the hypotensive activities of Practolol.	Approved
Pramipexole	The risk or severity of adverse effects can be increased when Pramipexole is combined with Felodipine.	Approved, Investigational
Pranoprofen	The therapeutic efficacy of Felodipine can be decreased when used in combination with Pranoprofen.	Experimental, Investigational
Pravastatin	The serum concentration of Pravastatin can be increased when it is combined with Felodipine.	Approved
Prazosin	The risk or severity of hypotension can be increased when Prazosin is combined with Felodipine.	Approved
Prednisolone	The serum concentration of Prednisolone can be increased when it is combined with Felodipine.	Approved, Vet Approved
Prednisone	The serum concentration of Prednisone can be increased when it is combined with Felodipine.	Approved, Vet Approved
Primidone	Primidone may increase the hypotensive activities of Felodipine.	Approved, Vet Approved
Progesterone	The metabolism of Progesterone can be decreased when combined with Felodipine.	Approved, Vet Approved
Proglumetacin	The therapeutic efficacy of Felodipine can be decreased when used in combination with Proglumetacin.	Experimental
Promazine	The risk or severity of hypotension can be increased when Promazine is combined with Felodipine.	Approved, Vet Approved
Propacetamol	The therapeutic efficacy of Felodipine can be decreased when used in combination with Propacetamol.	Approved, Investigational
Propericiazine	The risk or severity of hypotension can be increased when Propericiazine is combined with Felodipine.	Approved, Investigational
Propiomazine	The risk or severity of hypotension can be increased when Propiomazine is combined with Felodipine.	Approved
Propiverine	The risk or severity of hypotension can be increased when Propiverine is combined with Felodipine.	Approved, Investigational
Propofol	The risk or severity of adverse effects can be increased when Propofol is combined with Felodipine.	Approved, Investigational, Vet Approved
Propranolol	The serum concentration of Propranolol can be increased when it is combined with Felodipine.	Approved, Investigational
Propyphenazone	The therapeutic efficacy of Felodipine can be decreased when used in combination with Propyphenazone.	Experimental
Proquazone	The therapeutic efficacy of Felodipine can be decreased when used in combination with Proquazone.	Experimental
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Felodipine.	Approved
Quetiapine	The risk or severity of hypotension can be increased when Quetiapine is combined with Felodipine.	Approved
Quinapril	Quinapril may increase the hypotensive activities of Felodipine.	Approved, Investigational
Quinaprilat	Felodipine may increase the hypotensive activities of Quinaprilat.	Experimental
Quinidine	The serum concentration of Quinidine can be decreased when it is combined with Felodipine.	Approved, Investigational
Quinine	The metabolism of Felodipine can be increased when combined with Quinine.	Approved
Ramipril	Ramipril may increase the hypotensive activities of Felodipine.	Approved
Ramiprilat	Felodipine may increase the hypotensive activities of Ramiprilat.	Experimental
Ranitidine	The serum concentration of Ranitidine can be increased when it is combined with Felodipine.	Approved
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Felodipine.	Approved, Investigational
Rapacuronium	Felodipine may increase the neuromuscular blocking activities of Rapacuronium.	Withdrawn
Rasagiline	Rasagiline may increase the hypotensive activities of Felodipine.	Approved
Ravuconazole	The therapeutic efficacy of Ravuconazole can be increased when used in combination with Felodipine.	Investigational
Regorafenib	The serum concentration of Regorafenib can be increased when it is combined with Felodipine.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Remifentanil is combined with Felodipine.	Approved
Remikiren	Remikiren may increase the hypotensive activities of Felodipine.	Approved
Repaglinide	The metabolism of Repaglinide can be decreased when combined with Felodipine.	Approved, Investigational
Rescinnamine	Felodipine may increase the hypotensive activities of Rescinnamine.	Approved
Reserpine	The serum concentration of Reserpine can be increased when it is combined with Felodipine.	Approved, Investigational
Rhodamine 6G	The serum concentration of Rhodamine 6G can be increased when it is combined with Felodipine.	Experimental
Ribociclib	The serum concentration of Felodipine can be increased when it is combined with Ribociclib.	Approved, Investigational
Rifampicin	The metabolism of Felodipine can be increased when combined with Rifampicin.	Approved
Rifamycin	The metabolism of Felodipine can be increased when combined with Rifamycin.	Investigational
Rifapentine	The metabolism of Felodipine can be increased when combined with Rifapentine.	Approved, Investigational
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Felodipine.	Approved, Investigational
Rilmenidine	Rilmenidine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Rimexolone	The metabolism of Felodipine can be increased when combined with Rimexolone.	Approved
Riociguat	Felodipine may increase the hypotensive activities of Riociguat.	Approved
Risperidone	Felodipine may increase the hypotensive activities of Risperidone.	Approved, Investigational
Ritonavir	The serum concentration of Ritonavir can be increased when it is combined with Felodipine.	Approved, Investigational
Rituximab	Felodipine may increase the hypotensive activities of Rituximab.	Approved
Rivaroxaban	The serum concentration of Rivaroxaban can be increased when it is combined with Felodipine.	Approved
Rivoglitazone	The metabolism of Rivoglitazone can be decreased when combined with Felodipine.	Experimental, Investigational
Robenacoxib	The therapeutic efficacy of Felodipine can be decreased when used in combination with Robenacoxib.	Experimental, Vet Approved
Rocuronium	Felodipine may increase the neuromuscular blocking activities of Rocuronium.	Approved
Rofecoxib	The therapeutic efficacy of Felodipine can be decreased when used in combination with Rofecoxib.	Approved, Investigational, Withdrawn
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Felodipine.	Approved, Investigational
Ropinirole	The risk or severity of adverse effects can be increased when Ropinirole is combined with Felodipine.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Ropivacaine is combined with Felodipine.	Approved
Rosiglitazone	The metabolism of Rosiglitazone can be decreased when combined with Felodipine.	Approved, Investigational
Rotigotine	The risk or severity of adverse effects can be increased when Rotigotine is combined with Felodipine.	Approved
Rucaparib	The serum concentration of Rucaparib can be increased when it is combined with Felodipine.	Approved, Investigational
Sacubitril	The risk or severity of adverse effects can be increased when Sacubitril is combined with Felodipine.	Approved
Safinamide	Safinamide may increase the hypotensive activities of Felodipine.	Approved, Investigational
Safrazine	Safrazine may increase the hypotensive activities of Felodipine.	Withdrawn
Salicylamide	The therapeutic efficacy of Felodipine can be decreased when used in combination with Salicylamide.	Approved
Salicylic acid	The therapeutic efficacy of Felodipine can be decreased when used in combination with Salicylic acid.	Approved, Investigational, Vet Approved
Salsalate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Salsalate.	Approved
Saprisartan	Felodipine may increase the hypotensive activities of Saprisartan.	Experimental
Saquinavir	The metabolism of Felodipine can be decreased when combined with Saquinavir.	Approved, Investigational
Sarilumab	The therapeutic efficacy of Felodipine can be decreased when used in combination with Sarilumab.	Approved, Investigational
SC-236	The therapeutic efficacy of Felodipine can be decreased when used in combination with SC-236.	Experimental, Investigational
Secobarbital	Secobarbital may increase the hypotensive activities of Felodipine.	Approved, Vet Approved
Selegiline	Selegiline may increase the hypotensive activities of Felodipine.	Approved, Investigational, Vet Approved
Selexipag	The serum concentration of Selexipag can be increased when it is combined with Felodipine.	Approved
Sennosides	The therapeutic efficacy of Sennosides can be decreased when used in combination with Felodipine.	Approved
Sertaconazole	The therapeutic efficacy of Sertaconazole can be increased when used in combination with Felodipine.	Approved, Investigational
Sevoflurane	The risk or severity of adverse effects can be increased when Sevoflurane is combined with Felodipine.	Approved, Vet Approved
Sildenafil	Sildenafil may increase the antihypertensive activities of Felodipine.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Felodipine.	Approved
Siltuximab	The serum concentration of Felodipine can be decreased when it is combined with Siltuximab.	Approved, Investigational
Simeprevir	The serum concentration of Felodipine can be increased when it is combined with Simeprevir.	Approved
Simvastatin	The serum concentration of Simvastatin can be increased when it is combined with Felodipine.	Approved
Sirolimus	The serum concentration of Sirolimus can be increased when it is combined with Felodipine.	Approved, Investigational
Sitagliptin	The serum concentration of Sitagliptin can be increased when it is combined with Felodipine.	Approved, Investigational
Sitaxentan	Felodipine may increase the hypotensive activities of Sitaxentan.	Approved, Investigational, Withdrawn
Sodium phosphate, monobasic	The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Felodipine.	Approved
Sodium sulfate	The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Felodipine.	Approved, Vet Approved
Sodium tartrate	The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Felodipine.	Approved
Sofosbuvir	The serum concentration of Sofosbuvir can be increased when it is combined with Felodipine.	Approved
Somatostatin	The serum concentration of Somatostatin can be increased when it is combined with Felodipine.	Approved, Investigational
Sorafenib	The serum concentration of Sorafenib can be increased when it is combined with Felodipine.	Approved, Investigational
Sorbitol	The therapeutic efficacy of Sorbitol can be decreased when used in combination with Felodipine.	Approved
Sotalol	The risk or severity of adverse effects can be increased when Sotalol is combined with Felodipine.	Approved
Sparfloxacin	The serum concentration of Sparfloxacin can be increased when it is combined with Felodipine.	Approved, Investigational
Sphingosine	The serum concentration of Sphingosine can be increased when it is combined with Felodipine.	Experimental
Spirapril	Felodipine may increase the hypotensive activities of Spirapril.	Approved
Spironolactone	The risk or severity of adverse effects can be increased when Spironolactone is combined with Felodipine.	Approved
St. John's Wort	The serum concentration of Felodipine can be decreased when it is combined with St. John's Wort.	Approved, Investigational, Nutraceutical
Stanolone	The serum concentration of Stanolone can be increased when it is combined with Felodipine.	Illicit, Investigational
Stanolone acetate	The serum concentration of Stanolone acetate can be increased when it is combined with Felodipine.	Experimental
Stiripentol	The serum concentration of Felodipine can be increased when it is combined with Stiripentol.	Approved
Streptokinase	The risk or severity of adverse effects can be increased when Streptokinase is combined with Felodipine.	Approved, Investigational
Sufentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Felodipine.	Approved, Investigational
Sulconazole	The therapeutic efficacy of Sulconazole can be increased when used in combination with Felodipine.	Approved
Sulfasalazine	The therapeutic efficacy of Felodipine can be decreased when used in combination with Sulfasalazine.	Approved
Sulindac	The therapeutic efficacy of Felodipine can be decreased when used in combination with Sulindac.	Approved, Investigational
Sumatriptan	The serum concentration of Sumatriptan can be increased when it is combined with Felodipine.	Approved, Investigational
Sunitinib	The serum concentration of Sunitinib can be increased when it is combined with Felodipine.	Approved, Investigational
Suprofen	The therapeutic efficacy of Felodipine can be decreased when used in combination with Suprofen.	Approved, Withdrawn
Suxibuzone	The therapeutic efficacy of Felodipine can be decreased when used in combination with Suxibuzone.	Experimental
Tacrine	The serum concentration of Tacrine can be increased when it is combined with Felodipine.	Investigational, Withdrawn
Tadalafil	Tadalafil may increase the antihypertensive activities of Felodipine.	Approved, Investigational
Talinolol	The serum concentration of Talinolol can be increased when it is combined with Felodipine.	Investigational
Talniflumate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Talniflumate.	Approved
Tamoxifen	The serum concentration of Tamoxifen can be increased when it is combined with Felodipine.	Approved
Tamsulosin	The risk or severity of hypotension can be increased when Tamsulosin is combined with Felodipine.	Approved, Investigational
Taurocholic Acid	The serum concentration of Taurocholic Acid can be increased when it is combined with Felodipine.	Experimental
Technetium Tc-99m sestamibi	The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Felodipine.	Approved, Investigational
Tegaserod	The therapeutic efficacy of Tegaserod can be decreased when used in combination with Felodipine.	Approved, Investigational, Withdrawn
Telaprevir	The metabolism of Felodipine can be decreased when combined with Telaprevir.	Approved, Withdrawn
Telithromycin	The metabolism of Felodipine can be decreased when combined with Telithromycin.	Approved
Telmisartan	Telmisartan may increase the hypotensive activities of Felodipine.	Approved, Investigational
Temocapril	Felodipine may increase the hypotensive activities of Temocapril.	Experimental, Investigational
Temsirolimus	The serum concentration of Temsirolimus can be increased when it is combined with Felodipine.	Approved
Tenidap	The therapeutic efficacy of Felodipine can be decreased when used in combination with Tenidap.	Experimental
Teniposide	The serum concentration of Teniposide can be increased when it is combined with Felodipine.	Approved
Tenoxicam	The therapeutic efficacy of Felodipine can be decreased when used in combination with Tenoxicam.	Approved
Tepoxalin	The therapeutic efficacy of Felodipine can be decreased when used in combination with Tepoxalin.	Vet Approved
Terazosin	The risk or severity of hypotension can be increased when Terazosin is combined with Felodipine.	Approved
Terconazole	The therapeutic efficacy of Terconazole can be increased when used in combination with Felodipine.	Approved
Terfenadine	The serum concentration of Terfenadine can be increased when it is combined with Felodipine.	Approved, Withdrawn
Testosterone propionate	The serum concentration of Testosterone propionate can be increased when it is combined with Felodipine.	Approved, Investigational, Vet Approved, Withdrawn
Tetracycline	The serum concentration of Tetracycline can be increased when it is combined with Felodipine.	Approved, Vet Approved
Tetrahydropalmatine	Felodipine may increase the hypotensive activities of Tetrahydropalmatine.	Investigational
Thalidomide	The risk or severity of adverse effects can be increased when Thalidomide is combined with Felodipine.	Approved, Investigational, Withdrawn
Theophylline	Theophylline may increase the antihypertensive activities of Felodipine.	Approved
Thiamylal	Thiamylal may increase the hypotensive activities of Felodipine.	Approved, Vet Approved
Thiopental	Thiopental may increase the hypotensive activities of Felodipine.	Approved, Vet Approved
Thioproperazine	The risk or severity of hypotension can be increased when Thioproperazine is combined with Felodipine.	Approved
Thioridazine	The serum concentration of Thioridazine can be increased when it is combined with Felodipine.	Approved, Withdrawn
Tiaprofenic acid	The therapeutic efficacy of Felodipine can be decreased when used in combination with Tiaprofenic acid.	Approved
Ticagrelor	The serum concentration of Ticagrelor can be increased when it is combined with Felodipine.	Approved
Ticrynafen	Felodipine may increase the hypotensive activities of Ticrynafen.	Withdrawn
Timolol	The serum concentration of Timolol can be increased when it is combined with Felodipine.	Approved
Tinoridine	The therapeutic efficacy of Felodipine can be decreased when used in combination with Tinoridine.	Investigational
Tioconazole	The therapeutic efficacy of Tioconazole can be increased when used in combination with Felodipine.	Approved
Tipranavir	The metabolism of Felodipine can be decreased when combined with Tipranavir.	Approved, Investigational
Tizanidine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Felodipine.	Approved, Investigational
Tocilizumab	The serum concentration of Felodipine can be decreased when it is combined with Tocilizumab.	Approved
Tocopherylquinone	Felodipine may increase the hypotensive activities of Tocopherylquinone.	Experimental, Investigational
Tolazoline	The risk or severity of hypotension can be increased when Tolazoline is combined with Felodipine.	Approved, Vet Approved
Tolcapone	The risk or severity of adverse effects can be increased when Tolcapone is combined with Felodipine.	Approved, Withdrawn
Tolfenamic Acid	The therapeutic efficacy of Felodipine can be decreased when used in combination with Tolfenamic Acid.	Approved, Investigational
Tolmetin	The therapeutic efficacy of Felodipine can be decreased when used in combination with Tolmetin.	Approved
Tolonidine	Felodipine may increase the hypotensive activities of Tolonidine.	Experimental
Toloxatone	Toloxatone may increase the hypotensive activities of Felodipine.	Approved
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Felodipine.	Approved
Topiramate	The serum concentration of Topiramate can be increased when it is combined with Felodipine.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Felodipine.	Approved, Investigational
Torasemide	The metabolism of Torasemide can be decreased when combined with Felodipine.	Approved
Trandolapril	Trandolapril may increase the hypotensive activities of Felodipine.	Approved
Tranylcypromine	Tranylcypromine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Trastuzumab emtansine	The serum concentration of Trastuzumab emtansine can be increased when it is combined with Felodipine.	Approved, Investigational
Travoprost	Travoprost may increase the hypotensive activities of Felodipine.	Approved
Trazodone	The risk or severity of hypotension can be increased when Trazodone is combined with Felodipine.	Approved, Investigational
Treprostinil	The serum concentration of Treprostinil can be increased when it is combined with Felodipine.	Approved, Investigational
Tretinoin	The risk or severity of adverse effects can be increased when Tretinoin is combined with Felodipine.	Approved, Investigational, Nutraceutical
Triamterene	The risk or severity of adverse effects can be increased when Triamterene is combined with Felodipine.	Approved
Trichlormethiazide	Trichlormethiazide may increase the hypotensive activities of Felodipine.	Approved, Vet Approved
Trifluoperazine	The risk or severity of hypotension can be increased when Trifluoperazine is combined with Felodipine.	Approved, Investigational
Trimazosin	The risk or severity of hypotension can be increased when Trimazosin is combined with Felodipine.	Experimental
Trimethaphan	Trimethaphan may increase the hypotensive activities of Felodipine.	Approved, Investigational
Trimipramine	The risk or severity of hypotension can be increased when Trimipramine is combined with Felodipine.	Approved
Troglitazone	The metabolism of Troglitazone can be decreased when combined with Felodipine.	Investigational, Withdrawn
Trolamine salicylate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Trolamine salicylate.	Approved
Troleandomycin	The metabolism of Felodipine can be decreased when combined with Troleandomycin.	Approved
Tubocurarine	Felodipine may increase the neuromuscular blocking activities of Tubocurarine.	Approved
Ubidecarenone	The serum concentration of Ubidecarenone can be increased when it is combined with Felodipine.	Approved, Investigational, Nutraceutical
Udenafil	Udenafil may increase the antihypertensive activities of Felodipine.	Approved, Investigational
Umeclidinium	The serum concentration of Umeclidinium can be increased when it is combined with Felodipine.	Approved
Unoprostone	Felodipine may increase the hypotensive activities of Unoprostone.	Approved, Investigational
Urapidil	The risk or severity of hypotension can be increased when Urapidil is combined with Felodipine.	Investigational
Valdecoxib	The therapeutic efficacy of Felodipine can be decreased when used in combination with Valdecoxib.	Approved, Investigational, Withdrawn
Valinomycin	The serum concentration of Valinomycin can be increased when it is combined with Felodipine.	Experimental
Valsartan	Valsartan may increase the hypotensive activities of Felodipine.	Approved, Investigational
Valspodar	The serum concentration of Valspodar can be increased when it is combined with Felodipine.	Investigational
Vardenafil	Vardenafil may increase the antihypertensive activities of Felodipine.	Approved
Vecuronium	Felodipine may increase the neuromuscular blocking activities of Vecuronium.	Approved
Velpatasvir	The serum concentration of Velpatasvir can be increased when it is combined with Felodipine.	Approved, Investigational
Vemurafenib	The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Felodipine.	Approved
Venetoclax	The serum concentration of Venetoclax can be increased when it is combined with Felodipine.	Approved, Investigational
Venlafaxine	The serum concentration of Venlafaxine can be increased when it is combined with Felodipine.	Approved
Verapamil	The risk or severity of hypotension can be increased when Verapamil is combined with Felodipine.	Approved
Vinblastine	The serum concentration of Vinblastine can be increased when it is combined with Felodipine.	Approved
Vincamine	Felodipine may increase the hypotensive activities of Vincamine.	Experimental
Vincristine	The excretion of Vincristine can be decreased when combined with Felodipine.	Approved, Investigational
Vinflunine	The serum concentration of Vinflunine can be increased when it is combined with Felodipine.	Approved, Investigational
Vinorelbine	The serum concentration of Vinorelbine can be increased when it is combined with Felodipine.	Approved, Investigational
Vismodegib	The serum concentration of Vismodegib can be increased when it is combined with Felodipine.	Approved, Investigational
Voriconazole	The metabolism of Felodipine can be decreased when combined with Voriconazole.	Approved, Investigational
Vortioxetine	The metabolism of Vortioxetine can be decreased when combined with Felodipine.	Approved, Investigational
Voxilaprevir	The serum concentration of Voxilaprevir can be increased when it is combined with Felodipine.	Approved, Investigational
Xipamide	Felodipine may increase the hypotensive activities of Xipamide.	Experimental
Yohimbine	Yohimbine may decrease the antihypertensive activities of Felodipine.	Approved, Investigational, Vet Approved
Zaltoprofen	The therapeutic efficacy of Felodipine can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Zidovudine	The serum concentration of Zidovudine can be increased when it is combined with Felodipine.	Approved
Ziprasidone	The risk or severity of hypotension can be increased when Ziprasidone is combined with Felodipine.	Approved
Zofenopril	Felodipine may increase the hypotensive activities of Zofenopril.	Experimental
Zomepirac	The therapeutic efficacy of Felodipine can be decreased when used in combination with Zomepirac.	Withdrawn
Zuclopenthixol	The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Felodipine.	Approved, Investigational

Food Interactions

• Grapefruit down regulates post-translational expression of CYP3A4, the major metabolizing enzyme of nifedipine. Grapefruit, in all forms (e.g. whole fruit, juice and rind), can significantly increase serum levels of nifedipine and may cause toxicity. Avoid grapefruit products while on this medication.
• Take without regard to meals.

References

Synthesis Reference

Vinay Sharma, "Preparation of micron-size felodipine particles by microfluidization." U.S. Patent US20020086061, issued July 04, 2002.

US20020086061

General References

1. Dunselman PH, Edgar B: Felodipine clinical pharmacokinetics. Clin Pharmacokinet. 1991 Dec;21(6):418-30. [PubMed:1782737]

External Links

Human Metabolome Database

HMDB0015158

KEGG Drug

D00319

PubChem Compound

3333

PubChem Substance

46506968

ChemSpider

3216

BindingDB

189379

ChEBI

585948

ChEMBL

CHEMBL1480

Therapeutic Targets Database

DAP000487

PharmGKB

PA449591

IUPHAR

4190

Guide to Pharmacology

GtP Drug Page

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

PDRhealth

PDRhealth Drug Page

Wikipedia

Felodipine

ATC Codes

C08CA02 — Felodipine

• C08CA — Dihydropyridine derivatives
• C08C — SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
• C08 — CALCIUM CHANNEL BLOCKERS
• C — CARDIOVASCULAR SYSTEM

C09BB05 — Ramipril and felodipine

• C09BB — ACE inhibitors and calcium channel blockers
• C09B — ACE INHIBITORS, COMBINATIONS
• C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
• C — CARDIOVASCULAR SYSTEM

AHFS Codes

• 24:28.08 — Dihydropyridines

FDA label

Download (228 KB)

MSDS

Download (55.4 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Healthy Volunteers	1
1	Completed	Treatment	Food-Drug Interactions	1
3	Completed	Prevention	Atherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus	1
3	Completed	Treatment	BMI >30 kg/m2 / High Blood Pressure (Hypertension)	1
4	Completed	Prevention	Disorders Related to Lung Transplantation	1
4	Completed	Treatment	High Blood Pressure (Hypertension)	2
4	Completed	Treatment	High Blood Pressure (Hypertension) / Left Ventricular Hypertrophy	1
4	Unknown Status	Treatment	High Blood Pressure (Hypertension) / Sexual Dysfunctions	1
Not Available	Completed	Not Available	Healthy Volunteers	2
Not Available	Completed	Not Available	High Blood Pressure (Hypertension)	1
Not Available	Completed	Treatment	High Blood Pressure (Hypertension)	1
Not Available	Unknown Status	Basic Science	High Blood Pressure (Hypertension) / Insulin Resistance / Microcirculation	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

• A-S Medication Solutions LLC
• AstraZeneca Inc.
• Atlantic Biologicals Corporation
• Bryant Ranch Prepack
• Cardinal Health
• Heartland Repack Services LLC
• Lake Erie Medical and Surgical Supply
• Liberty Pharmaceuticals
• Merck & Co.
• Murfreesboro Pharmaceutical Nursing Supply
• Mutual Pharmaceutical Co.
• Mylan
• Nucare Pharmaceuticals Inc.
• PD-Rx Pharmaceuticals Inc.
• Physicians Total Care Inc.
• Preferred Pharmaceuticals Inc.
• Prepackage Specialists
• Prepak Systems Inc.
• Prescript Pharmaceuticals
• Ranbaxy Laboratories
• Resource Optimization and Innovation LLC
• Richmond Pharmacy
• Sandhills Packaging Inc.
• UDL Laboratories
• Va Cmop Dallas
• Vangard Labs Inc.

Dosage forms

Form	Route	Strength
Tablet	Oral
Tablet, film coated	Oral	2.5 mg/1
Tablet, film coated, extended release	Oral	10 mg/1
Tablet, film coated, extended release	Oral	2.5 mg/1
Tablet, film coated, extended release	Oral	5 mg/1
Tablet, extended release	Oral	10 mg/1
Tablet, extended release	Oral	2.5 mg/1
Tablet, extended release	Oral	5 mg/1
Tablet, extended release	Oral	10 mg
Tablet, extended release	Oral	2.5 mg
Tablet, extended release	Oral	5 mg

Prices

Unit description	Cost	Unit
Plendil 10 mg 24 Hour tablet	3.17USD	tablet
Plendil er 10 mg tablet	3.05USD	tablet
Plendil 10 mg tablet sa	2.96USD	tablet
Felodipine 10 mg 24 Hour tablet	2.95USD	tablet
Plendil er 2.5 mg tablet	2.94USD	tablet
Felodipine er 10 mg tablet	2.72USD	tablet
Plendil er 5 mg tablet	2.6USD	tablet
Plendil 5 mg 24 Hour tablet	1.77USD	tablet
Plendil 2.5 mg 24 Hour tablet	1.76USD	tablet
Felodipine 5 mg 24 Hour tablet	1.67USD	tablet
Plendil 2.5 mg tablet sa	1.65USD	tablet
Plendil 5 mg tablet sa	1.65USD	tablet
Felodipine 2.5 mg 24 Hour tablet	1.57USD	tablet
Felodipine er 2.5 mg tablet	1.51USD	tablet
Felodipine er 5 mg tablet	1.51USD	tablet
Renedil 10 mg Extended-Release Tablet	1.22USD	tablet
Plendil 10 mg Extended-Release Tablet	1.15USD	tablet
Renedil 5 mg Extended-Release Tablet	0.81USD	tablet
Plendil 5 mg Extended-Release Tablet	0.77USD	tablet
Sandoz Felodipine 10 mg Extended-Release Tablet	0.73USD	tablet
Renedil 2.5 mg Extended-Release Tablet	0.6USD	tablet
Plendil 2.5 mg Extended-Release Tablet	0.57USD	tablet
Sandoz Felodipine 5 mg Extended-Release Tablet	0.48USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	145 °C	Not Available
water solubility	19.7 mg/L	Not Available
logP	3.86	SANGSTER (1994)
Caco2 permeability	-4.64	ADME Research, USCD

Predicted Properties

Property	Value	Source
Water Solubility	0.00715 mg/mL	ALOGPS
logP	4.36	ALOGPS
logP	3.44	ChemAxon
logS	-4.7	ALOGPS
pKa (Strongest Basic)	5.39	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	64.63 Å2	ChemAxon
Rotatable Bond Count	6	ChemAxon
Refractivity	99.2 m3·mol-1	ChemAxon
Polarizability	38.04 Å3	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9878
Blood Brain Barrier	-	0.83
Caco-2 permeable	+	0.8867
P-glycoprotein substrate	Substrate	0.5149
P-glycoprotein inhibitor I	Inhibitor	0.8563
P-glycoprotein inhibitor II	Non-inhibitor	0.8383
Renal organic cation transporter	Non-inhibitor	0.8664
CYP450 2C9 substrate	Non-substrate	0.8357
CYP450 2D6 substrate	Non-substrate	0.9116
CYP450 3A4 substrate	Substrate	0.6954
CYP450 1A2 substrate	Inhibitor	0.9106
CYP450 2C9 inhibitor	Inhibitor	0.8948
CYP450 2D6 inhibitor	Non-inhibitor	0.9232
CYP450 2C19 inhibitor	Inhibitor	0.8994
CYP450 3A4 inhibitor	Inhibitor	0.7959
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.9304
Ames test	Non AMES toxic	0.7849
Carcinogenicity	Non-carcinogens	0.7511
Biodegradation	Not ready biodegradable	0.9527
Rat acute toxicity	2.4526 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9455
hERG inhibition (predictor II)	Non-inhibitor	0.8734

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0udu-0139000000-085071c20c5d0c134d8f

Taxonomy

Description

This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Pyridines and derivatives

Sub Class

Hydropyridines

Direct Parent

Dihydropyridinecarboxylic acids and derivatives

Alternative Parents

Dichlorobenzenes / Dicarboxylic acids and derivatives / Aryl chlorides / Vinylogous amides / Methyl esters / Enoate esters / Amino acids and derivatives / Enamines / Dialkylamines / Azacyclic compoundsOrganopnictogen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds

show 5 more

Substituents

Dihydropyridinecarboxylic acid derivative / 1,2-dichlorobenzene / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Vinylogous amideAlpha,beta-unsaturated carboxylic ester / Enoate ester / Methyl ester / Amino acid or derivatives / Carboxylic acid ester / Carboxylic acid derivative / Secondary aliphatic amine / Enamine / Secondary amine / Azacycle / Organonitrogen compound / Hydrocarbon derivative / Organooxygen compound / Organic oxide / Amine / Organohalogen compound / Carbonyl group / Organopnictogen compound / Organic oxygen compound / Organic nitrogen compound / Organochloride / Aromatic heteromonocyclic compound

show 22 more

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

ethyl ester, dichlorobenzene, methyl ester, dihydropyridine (CHEBI:585948)

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 12:25